Fate Therapeutics, Inc.FATENASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank29
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$-127.02M
Near historical average
Percentile
P29
Within normal range
Streak
1 yr
Consecutive growthExpanding
Average
$-133.62M
Historical baseline
PeriodValueYoY Change
2025$-127.02M+28.1%
2024$-176.58M-2.5%
2023$-172.23M+41.5%
2022$-294.63M-39.5%
2021$-211.14M-68.9%
2020$-125.00M-32.7%
2019$-94.20M-47.9%
2018$-63.70M-56.5%
2017$-40.71M-31.6%
2016$-30.94M-